Autoimmune Disease Diagnosis Market Report 2025

The autoimmune disease diagnosis market size has grown strongly in recent years. It will grow from $5.84 billion in 2024 to $6.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the rising incidence of autoimmune diseases, emerging markets growth, increased healthcare expenditure, and high prevalence in women.

The autoimmune disease diagnosis market size is expected to see strong growth in the next few years. It will grow to $8.81 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to increased funding for autoimmune (ai) diagnostics, faster economic growth, growing awareness about autoimmune diseases, and biomarker discovery. Major trends in the forecast period include partnering with other players, investing in artificial intelligence companies, collaborating with the government, and developing at-home rapid test kits.

A surge in the prevalence of autoimmune diseases has significantly contributed to the expansion of the autoimmune disease diagnosis market. Notably, in February 2023, Multiple Sclerosis Australia reported a substantial increase in Multiple Sclerosis (MS) cases in Australia, with a recorded count of 33,335 patients in 2021. This figure reflects a notable surge of 30% (7,728 individuals) over the previous four years, from 25,607 in the preceding period. The escalating incidence of autoimmune disorders globally stands as a driving force behind the heightened demand and growth witnessed within the autoimmune disease diagnosis market.

The anticipated growth of the autoimmune disease diagnosis market is closely intertwined with the escalating healthcare expenditures observed in recent years. Healthcare expenditure, quantifying the total resources allocated to healthcare-related products and services, serves as a fundamental metric indicating population health and healthcare system efficacy. Heightened healthcare spending translates to expedited access to healthcare services, consequently leading to enhanced identification, treatment, and outcomes for individuals afflicted by autoimmune conditions. Notably, as of September 2023, the Centers for Medicare & Medicaid Services in the United States disclosed a 2.7 percent increase in national health spending, reaching a staggering $4.3 trillion in 2021, averaging $12,914 per individual and representing 18.3% of the Gross Domestic Product (GDP). This upward trajectory in healthcare expenditure remains a pivotal catalyst propelling advancements within the autoimmune disease diagnosis market.

Biosensors and nano biosensors stand as groundbreaking tools within the autoimmune disease diagnosis market, offering rapid and efficient antibody detection. These cutting-edge technologies are favored for their cost-effectiveness, exceptional sensitivity, user-friendly nature, multiplexing capabilities, and swift diagnostic outcomes. Beyond merely measuring antibody quantities in human blood serum with remarkable sensitivity, they also gauge antibody activity utilizing portable optical label-free biosensors grounded in spectral correlation interferometry. This point-of-care technology delivers a more integrated, informative, timely, and precise diagnosis of autoimmune diseases compared to traditional methods, enhancing the diagnostic landscape significantly.

Leading entities operating in the autoimmune disease diagnosis market are directing their efforts toward pioneering solutions such as the Phadia 2500+ series autoimmune testing instruments, aiming to better cater to the demands of their clientele. These antibody instruments are instrumental in conducting laboratory tests designed to identify autoimmune disorders. Particularly noteworthy, in May 2022, Thermo Fisher Scientific Inc., a prominent US-based company specializing in life sciences solutions, specialized diagnostics, laboratory services, and biotechnology, introduced the innovative Phadia 2500+ range of equipment. This advanced series of instruments offers expanded capabilities, facilitating integration and further automation for EliA autoimmune diagnostics. Its enhanced functionalities assist in diagnosing various autoimmune diseases, including but not limited to celiac disease, connective tissue disease (CTD), antiphospholipid syndrome (APS), rheumatoid arthritis, autoimmune thyroid disease, and autoimmune liver disease, catering to the diverse spectrum of autoimmune conditions.

Major companies operating in the autoimmune disease diagnosis market include Siemens Healthineers AG, Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Danaher Corporation, AESKU Diagnostics GmbH & Co. KG, Trinity Biotech plc., bioMérieux SA, SQI Diagnostics, SCHILLER Healthcare India Pvt. Ltd, Covidien Healthcare India Private Limited, Philips Healthcare India, Fisher & Paykel Healthcare India Private Limited, Smith’s Medical India Pvt Ltd, Agappe Diagnostics Ltd, Accord Medical Products Private Limited, Lepu Medical Technology Company (Beijing) Co., Ltd, Yuwell - Jiangsu Yuyue Medical Equipment & Supply Co., Ltd, Shanghai Runda Medical Technology Co., Ltd, GE Healthcare China Co., Ltd, Roche Holding AG, Koninklijke Philips, Theradiag, Sanofi, Themis Bioscience, Becton Dickinson and Company.

North America was the largest region in the autoimmune disease diagnosis market in 2024. Western Europe was the second largest region in the autoimmune disease diagnosis market share. The regions covered in the autoimmune disease diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the autoimmune disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The autoimmune disease diagnosis market includes revenue earned by diagnostic assay kits, reagents, consumables, and instruments used for the diagnosis of autoimmune diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Autoimmune diseases are characterized by the body's production of antibodies that target and attack its own healthy cells, leading to their destruction. Conditions falling under this category include Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus, and inflammatory bowel syndrome. The diagnosis of these diseases typically involves immunological tests.

The primary types of tests used for autoimmune disease diagnosis include routine laboratory tests, autoantibody tests, immunologic tests, and other specialized tests. Autoantibody tests play a crucial role in aiding the diagnosis of autoimmune diseases. Various products, such as consumables and assay kits, as well as instruments, are employed in these diagnostic processes. These diagnostic tools find application in diverse sectors, including clinical laboratories, hospitals, and other relevant healthcare settings.

The autoimmune disease diagnosis market research report is one of a series of new reports that provides autoimmune disease diagnosis market statistics, including autoimmune disease diagnosis industry global market size, regional shares, competitors with a autoimmune disease diagnosis market share, detailed autoimmune disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune disease diagnosis industry. This autoimmune disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.